• Sean O'Mahony, Susan Nathan, Roozbeh Mohajer, Philip Bonomi, Marta Batus, Mary Jo Fidler, Kalani Wells, Naomi Kern, Shannon Sims, and Darpan Amin.
• Section of Palliative Medicine, Section of Medical Oncology, Rush University Medical Center, Chicago, IL, USA.
• Am J Hosp Palliat Care. 2016 May 1; 33 (4): 374-80.

ObjectivesPatients with advanced non-small cell lung cancer (NSCLC) have a life expectancy of less than 1 year. Therefore, it is important to maximize their quality of life and find a tool that can more accurately predict survival.MaterialsThe Palliative Performance Scale (PPS) is used to predict survival for patients with advanced disease based on functional dimensions. The value of the PPS in ambulatory patients with cancer has not been examined to date. The Lung Cancer Symptom Scale (LCSS) measures six major symptoms and their effect on symptomatic distress and activity. We evaluated 62 patients with stage III or IV NSCLC and Eastern Cooperative Oncology Group (ECOG) Scale Score ≥1 at baseline in a thoracic oncology clinic. In all, 62 patients had LCSS and PPS evaluated at baseline and 54 patients had 4-week follow-up using LCSS, PPS, and ECOG.ResultsFifty-four patients completed baseline and follow-up. Mean age was 63.7 years. Sixty-three percent were receiving chemotherapy at evaluation. Seventeen patients died. Mean baseline measures were LCSS 6.18 (1-14); PPS 66.6 (40-90); and ECOG 1.82 (1-4). Censored survival times were calculated from enrollment of the first patient for 380 days. A proportional hazardous model was computed for survival status. Hazard ratios for death were 1.25 (P = .013) for LCSS, 2.12 (P = .027) for ECOG, and 1.02 for PPS (P = .49).ConclusionsThe LCSS predicted prognosis best in this study. The PPS did not accurately predict prognosis in our patient population.© The Author(s) 2015.

26 keywords...

hide…